Laronib 100mg Larotrectinib Capsule In Pakistan

Laronib 100 mg Capsules (Larotrectinib) – In Pakistan

Product Overview

Laronib 100 mg Capsules contain Larotrectinib, a targeted anticancer medicine used for the treatment of certain solid tumors that have a specific NTRK gene fusion. Unlike many traditional cancer treatments, larotrectinib targets the molecular abnormality driving the cancer rather than focusing only on the location where the tumor started.

Active Ingredient

• Generic Name: Larotrectinib
• Strength: 100 mg
• Dosage Form: Capsule
• Therapeutic Class: Targeted anticancer therapy
• Target: Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions

Uses of Laronib 100 mg

Laronib (Larotrectinib) may be prescribed for patients with locally advanced, metastatic, or surgically difficult-to-treat solid tumors that have an NTRK gene fusion.

Treatment may be considered when:

• The tumor has an NTRK gene fusion confirmed by an appropriate laboratory test.
• Surgery would cause significant complications or is not an appropriate option.
• The cancer has spread to other parts of the body.

Larotrectinib can be used in both adult and pediatric patients, when clinically appropriate.

How Larotrectinib Works

Larotrectinib is a TRK inhibitor. NTRK gene fusions can produce abnormal TRK proteins that continuously send signals encouraging cancer-cell growth.

Larotrectinib blocks these TRK proteins and helps interfere with the signals responsible for tumor growth and survival.

Dosage and Administration

The appropriate dose should be determined by the treating oncologist according to the patient's age, clinical condition, liver function, other medicines, and treatment response.

For adults and children with a body surface area of at least 1.0 m², the commonly recommended dosage is 100 mg twice daily.

The capsules should be swallowed whole with water and may generally be taken with or without food. Do not crush or chew the capsules unless specifically instructed by a healthcare professional.

Important Safety Information

Larotrectinib is a prescription anticancer medicine and should be used under the supervision of an experienced oncology specialist.

Important precautions include monitoring for:

• Liver problems
• Neurological effects
• Dizziness or impaired coordination
• Drug interactions
• Pregnancy-related risks

Your doctor may perform blood tests, including liver-function tests, during treatment.

Common Side Effects

Possible side effects may include:

• Fatigue
• Nausea
• Constipation
• Vomiting
• Dizziness
• Cough
• Increased liver enzymes
• Diarrhea
• Headache
• Muscle or joint pain

Side effects vary between patients. Contact the treating doctor if symptoms are persistent, severe, or unusual.

Serious Side Effects

Seek prompt medical attention for symptoms such as:

• Severe dizziness or problems with coordination
• Significant changes in mental function
• Severe or persistent liver-related symptoms
• Yellowing of the skin or eyes
• Dark urine
• Severe abdominal pain
• Serious allergic reactions

Drug Interactions

Larotrectinib can interact with other medicines, particularly medicines that affect CYP3A4 and other drug-metabolizing pathways.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins, and herbal products you are taking before starting treatment.

Pregnancy and Breastfeeding

Larotrectinib may cause fetal harm. Women who can become pregnant should discuss appropriate contraception with their healthcare provider during treatment and for the recommended period after the final dose.

Breastfeeding should generally be avoided during treatment and for the period recommended by the prescribing physician.

Storage

Store Laronib 100 mg capsules according to the manufacturer's instructions, generally:

• At room temperature
• Away from excessive heat and moisture
• In the original packaging
• Out of reach of children

Always follow the storage conditions printed on the product packaging.

Laronib 100 mg in Pakistan

Laronib 100 mg (Larotrectinib) is a specialized oncology medicine intended for patients whose tumors have an appropriate NTRK gene fusion. Availability and registration status can vary in Pakistan, so patients should obtain the medicine through a licensed pharmacy or authorized medical supplier and verify the product's packaging, manufacturer, batch number, and expiry date.

Important Note

Laronib 100 mg should not be started, stopped, or dose-adjusted without the advice of an oncologist. Molecular testing is important because larotrectinib is specifically intended for cancers with qualifying NTRK gene fusions.

Disclaimer: This information is for educational purposes only and does not replace advice from a qualified doctor, pharmacist, or oncologist.